Catalog No.
Product Name
Application
Product Information
Citations
-
Cholecystokinin Receptor Antagonist
T-0632 is a potent cholecystokinin (CCK) A receptor antagonist that effectively inhibits the binding of [125I]CCK-8 to rat pancreatic CCK A receptors, demonstrating a K_i value of 0.24 nM. It shows significant selectivity in blocking CCK-8-induced pancreatic enzyme release, with an IC_50 value of 5.0 nM. T-0632 exhibits reversible antagonistic effects in rabbit gallbladder smooth muscle, distinguishing it from other CCK A antagonists. This compound is valuable for researching the physiological roles of CCK receptors and their impact on gastrointestinal function. -
Cholecystokinin Receptor Antagonist
LY 225910 is a selective antagonist of the cholecystokinin receptor (CCK2 receptor), primarily impacting the excitatory response associated with morphine. By inhibiting this receptor, LY 225910 plays a significant role in morphine sensitization, making it a valuable tool in research focused on pain management and addiction. Its application can aid in understanding the mechanisms underlying opioid response and potential therapeutic strategies. -
Cholecystokinin Receptor Antagonist
Pranazepide is a selective antagonist of the cholecystokinin-A receptor (CCK-A), implicated in regulating gastrointestinal functions and satiety. This compound exhibits significant biological activity by modulating neural signaling pathways associated with appetite control and gastrointestinal motility. Pranazepide is commonly utilized in pharmacological research focused on obesity, anxiolytic effects, and the role of CCK in the central nervous system. -
CCK2 Receptor Antagonist
JNJ-26070109 is a selective antagonist of the cholecystokinin 2 (CCK2) receptor, exhibiting high-affinity and competitive binding. With favorable pharmacokinetic properties, it demonstrates pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. This compound is particularly relevant for research into gastroesophageal reflux disease, as CCK2 receptors play a dual role in regulating gastric acid secretion and the growth of gastrointestinal mucosa. -
CCK Derivative
Cholecystokinin Octapeptide, desulfated TFA is a synthetic derivative of the endogenous hormone cholecystokinin (CCK), which primarily targets CCK receptors. This peptide exhibits key biological activities related to digestion and satiety regulation, making it valuable in studies of gastrointestinal physiology and appetite control. It is frequently utilized in research applications investigating the role of CCK in various biological processes, including pancreatic enzyme secretion and gastric motility. -
Cholecystokinin Receptor Antagonist
A-65186 is a cholecystokinin (CCK) A receptor antagonist that effectively inhibits CCK8-induced amylase secretion. This compound exhibits high binding affinity for pancreatic CCK-A receptors and demonstrates over 500-fold selectivity for CCK-A over CCK-B receptors. It serves as a valuable tool in research focused on gastrointestinal physiology and the role of CCK signaling in pancreatic function. -
Cholecystokinin Receptor Antagonist
(Rac)-Sograzepide functions as an antagonist of the cholecystokinin B (CCK-B) receptor, effectively inhibiting its activity. This compound is primarily utilized in research focused on modulating gastric acid secretion and exploring potential therapeutic strategies for gastrointestinal disorders. Its role in receptor inhibition makes it valuable for studies related to the regulation of digestive processes and related physiological pathways. -
Peptide Hormone
CCK (26-31) sulfated is a peptide hormone fragment that plays a crucial role in gastrointestinal function and neuroendocrine signaling. This bioactive peptide is involved in stimulating digestive processes, modulating appetite, and influencing anxiety-related behavior. Research applications include studies on gut-brain interactions, appetite regulation, and the pharmacological effects of peptide hormones in both physiological and pathological contexts. -
Gastrin/CCK-B Antagonist
CCK-B Receptor Antagonist 2 is a potent antagonist of the Gastrin/CCK-B receptor, exhibiting an IC50 of 0.43 nM. This compound also demonstrates inhibitory activity against the gastrin/CCK-A receptor with an IC50 of 1.82 μM. CCK-B Receptor Antagonist 2 serves as a valuable tool for research on gastrointestinal signaling and modulation of gastrin-related pathways, making it significant for studies concerning gastric function and disorders. -
Cholecystokinin Receptor Antagonist
Tarazepide is a potent antagonist of the cholecystokinin A (CCK-A) receptor. This compound inhibits CCK-A mediated signaling, demonstrating significant biological activity in modulating gastrointestinal functions and appetite regulation. Tarazepide is utilized in research applications related to digestion, metabolic disorders, and neurobiology, making it a valuable tool for studying the role of CCK receptors in various physiological processes. -
CCKB Receptor Antagonists
Pentagastrin meglumine is a selective antagonist of the Cholecystokinin B (CCKB) receptor, exhibiting an IC50 of 11 nM for CCKB and 1100 nM for CCKA. It plays a significant role in enhancing gastric mucosal defense mechanisms against acidity and provides protective effects on the gastric mucosa from experimental injury. This compound is valuable for research applications focused on gastrointestinal health and pathology. -
CCK2/gastrin Receptor Antagonist
Gastrazole is a potent and selective antagonist of the CCK2/gastrin receptor. This compound effectively reduces gastric acid levels and has been shown to inhibit gastrin-stimulated growth in pancreatic cancer cells. As such, Gastrazole is a valuable tool for research focused on gastrointestinal disorders and cancer biology. -
CCK2R Antagonist
GV150013X is a potent antagonist of the cholecystokinin-2/gastrin receptor (CCK2R), exhibiting a Ki value of 2.29 nM. This compound has demonstrated efficacy in attenuating central nervous system disorders, particularly in models of anxiety and panic disorder. Its application in research may provide valuable insights into the therapeutic potential for CCK2R modulation in neuropsychiatric conditions. -
CCK-B Receptor Antagonist
RP 72540 is a selective antagonist of the CCK-B receptor, exhibiting IC50 values of 2.4 nM, 1.2 nM, and 3.8 nM in guinea pig, rat, and mouse cerebral cortices, respectively. This compound effectively inhibits CCK-8-induced neuronal firing and demonstrates a dose-dependent reduction in gastric acid secretion. RP 72540 serves as a valuable tool in research applications aiming to elucidate the physiological roles of CCK-B receptors, particularly in the context of gastrointestinal processes and neurophysiology. -
Cholecystokinin Receptor
CI-1015 is a potent antagonist of the cholecystokinin B (CCK-B) receptor, which plays a critical role in gastrointestinal physiology and neurotransmission. This compound effectively inhibits CCK-B receptor activity, making it valuable for research into gastrointestinal disorders, anxiety, and pain modulation. Its specificity for the CCK-B receptor allows for the exploration of therapeutic avenues in conditions where CCK signaling is implicated. -
Appetite Suppressant
Ro 23-7014 is a cholecystokinin (CCK-7) analog that functions as an appetite suppressant. This compound modulates the central and peripheral pathways involved in energy homeostasis, making it valuable for research on obesity and metabolic disorders. Its ability to influence feeding behavior positions Ro 23-7014 as a relevant tool for exploring therapeutic targets in appetite regulation and weight management studies. -
Cholecystokinin Receptor
Mini Gastrin I, human is a truncated form of human gastrin, comprising amino acids 5-17 of the full peptide. It primarily targets the cholecystokinin receptor, playing a crucial role in gastrointestinal function by stimulating gastric acid secretion and promoting digestive enzyme release. This reagent is valuable for research in gastrointestinal physiology and the study of receptor signaling pathways associated with gastrin. -
CCKAR Small Molecule Agonist
CE-326597 is a small molecule agonist of the cholecystokinin A receptor (CCKAR). It selectively engages the lower region of the transmembrane domain pocket, offering unique insights into receptor activation that differ from the natural ligand CCK-8. This compound is valuable for studying metabolic disorders and gastrointestinal dysfunction, enabling researchers to explore the therapeutic potential of CCKAR modulation. -
CCK2R Antagonist
CI-988 meglumin is a potent cholecystokinin 2 receptor (CCK2R) antagonist. By inhibiting CCK2R, CI-988 meglumin plays a critical role in mitigating the gastrin-mediated cardioprotective effects associated with ischemia/reperfusion injury. This compound is valuable for research in cardiac physiology and pathophysiology, particularly in studies exploring receptor signaling and myocardial stress responses. -
C-terminal heptapeptide of CCK
CCK (27-33) is the C-terminal heptapeptide derived from cholecystokinin (CCK), which primarily targets CCK receptors. This peptide plays a significant role in stimulating gallbladder contraction and promoting pancreatic enzyme secretion, making it crucial for investigating digestive processes. CCK (27-33) is utilized in research applications focusing on gastrointestinal physiology and receptor signaling pathways. -
CCK-A Receptor Agonist
A71378 is a selective CCK-A receptor agonist with an IC50 of 0.4 nM for the pancreatic CCK-A receptor, and significantly higher IC50 values for the cortical CCK-B and gastrin receptors at 300 nM and 1,200 nM, respectively. This compound effectively stimulates pancreatic amylase secretion with an EC50 of 0.16 nM and induces ileal muscle contraction with an EC50 of 3.7 nM. A71378 is valuable for research applications focusing on gastrointestinal pharmacology and the role of CCK-A receptors in digestive processes. -
CCK2 Agonist
FE100726 is a potent Cholecystokinin 2 (CCK2) receptor agonist, exhibiting high binding affinity to the CCK2 receptor. This compound has been demonstrated to effectively stimulate gastric acid secretion in anesthetized rat models. FE100726 is valuable for research related to diabetes and gastrointestinal physiology, offering insights into the role of CCK2 signaling pathways. -
Cholecystokinin Receptor Inhibitor
Gastrazole free acid is a cholecystokinin receptor antagonist that demonstrates potential in inhibiting pancreatic cancer growth. By targeting gastrin receptors, this compound plays a crucial role in the modulation of gastric functions and may aid in the investigation of therapeutic strategies for gastrointestinal malignancies. Its utility in research provides insights into receptor-mediated pathways and cancer biology. -
CCK2 Antagonist
PD 136450 is a potent antagonist of cholecystokinin 2 (CCK2) receptors. This compound demonstrates significant biological activity, including anti-secretory, anxiolytic, and anti-ulcer effects. PD 136450 effectively inhibits gastric acid secretion with an IC50 of 1 mg/kg and significantly reduces hemorrhagic lesions in rat models, with an IC50 of 4.7 mg/kg. It is a valuable tool for investigating gastrointestinal disorders and evaluating potential therapeutic approaches in related pharmacological research. -
CCK-A/B Receptors Antagonist
Proglumide hemicalcium is a non-peptide antagonist of cholecystokinin (CCK)-A/B receptors. It selectively inhibits the actions of CCK in the central nervous system, demonstrating key biological activities such as the inhibition of gastric secretion and protection of the gastroduodenal mucosa. Additionally, Proglumide hemicalcium exhibits antiepileptic and antioxidant properties, making it a valuable reagent for research in gastrointestinal protection and neurological studies. -
CCK1R Agonist
PF-04756956 is a potent agonist of the type 1 cholecystokinin receptor (CCK1R) with an EC50 of 0.47 nM. This compound is valuable for studying the mechanisms underlying obesity and associated metabolic disorders. Its activity at CCK1R makes it a significant tool for investigating therapeutic strategies aimed at regulating appetite and metabolic function. -
CCK1-receptor Antagonist
JNJ-17156516 is a potent and selective antagonist of the cholecystokinin (CCK)1 receptor. This compound demonstrates significant biological activity in inhibiting CCK-induced signaling, making it valuable for research in gastrointestinal physiology and related disorders. Its oral bioavailability positions it as a useful tool in the exploration of CCK1 receptor functions and therapeutic applications. -
CCKB Receptor Antagonist
Spiroglumide is a selective cholecystokinin B (CCKB) receptor antagonist. It demonstrates significant biological activity through the inhibition of CCKB receptor signaling, making it valuable for studying the physiological roles of cholecystokinin in various biological systems. Research applications include the investigation of gastrointestinal disorders and the exploration of potential therapeutic strategies in conditions linked with dysregulated CCKB receptor activity. -
Cholecystokinin Receptor Agonist
ARL 15849XX is a potent agonist of the cholecystokinin receptor, specifically designed as an analog of cholecystokinin-8 (CCK-8). It effectively engages CCK receptors, stimulating pathways associated with gastrointestinal functions and satiety. This compound is valuable in research applications focusing on digestive physiology and neuropeptide signaling pathways. -
Cholecystokinin Receptor Agonist
Caerulein acetate is a decapeptide that functions as a potent agonist of the cholecystokinin receptor. It exhibits significant cholecystokinetic activity, promoting contraction of the gallbladder and facilitating bile duct function. This compound is widely used in research applications related to gastrointestinal motility and the study of digestive processes. -
CCKB Antagonist
PD 135158 is a selective antagonist of the CCKB receptor, exhibiting an IC50 of 2.8 nM in mouse cortex assays. This compound demonstrates notable anxiolytic properties, making it a valuable tool for research into anxiety disorders and related neuropharmacological studies. Its specificity and potency make PD 135158 suitable for investigating the role of CCKB receptors in various biological contexts. -
CCK-B Antagonist
LY262691 is a selective antagonist of the cholecystokinin B (CCK-B) receptor, known for its antipsychotic properties. This compound effectively reduces the activity of spontaneously firing A9 and A10 dopamine neurons, making it a valuable tool in antipsychotic research. Its mechanism offers insights into the modulation of dopaminergic signaling pathways related to psychiatric disorders. -
CCK Antagonist
LY 202769 is a cholecystokinin (CCK) and gastrin receptor antagonist, providing a valuable tool for investigating the roles of these receptors in physiological processes. This compound exhibits potent antagonistic activity, making it suitable for research into gastrointestinal disorders as well as central nervous system diseases. Its application can aid in understanding the mechanisms of action associated with CCK and gastrin receptors in these pathologies. -
Cholecystokinin Receptor Antagonist
Lorglumide is a potent cholecystokinin (CCK) receptor antagonist that effectively blocks the activity of CCK at its receptors. This compound is instrumental in studying the regulation of pancreatic secretion and growth. Lorglumide serves as a valuable tool for investigating gastrointestinal physiology and related disorders. -
CCK Receptor Antagonist
Cholecystokinin (27-32)-amide is a potent antagonist of the cholecystokinin (CCK) receptor, primarily interfering with CCK-mediated signaling pathways. This compound exhibits significant biological activity in regulating digestive processes and satiety. It is widely utilized in research applications focused on gastrointestinal function, neuropeptide signaling, and potential therapeutic interventions for related disorders. -
CCKB/Gastrin Receptor Antagonist
RP-69758 is a selective non-peptide antagonist of the cholecystokinin-B (CCKB)/gastrin receptor, demonstrating over 200-fold specificity for CCKB compared to CCKA receptors. This compound effectively inhibits CCK-8-induced neuronal firing in rat hippocampal slices and suppresses pentagastrin-induced gastric acid secretion in rats. RP-69758 serves as a valuable tool for investigating neurological disorders and gastrointestinal diseases in research applications. -
CCK Agonist
JMV 176 is a cholecystokinin (CCK) receptor agonist that exhibits its primary activity upon initial administration. Following a period of 3–4 hours, it transitions to function as a CCK antagonist. This dual-action characteristic makes JMV 176 valuable for research exploring CCK-related physiological processes and potential therapeutic applications in gastrointestinal disorders. -
CCK-A Receptor Antagonist
CHEMBL333994 is a selective antagonist of the Cholecystokinin A receptor (CCK-A receptor), exhibiting a potent inhibitory activity with an IC50 of 0.67 nM. This compound selectively targets peripheral CCK receptors and has been shown to increase CCK mRNA levels. CHEMBL333994 is useful in research related to chronic pancreatitis, providing insights into its therapeutic potential in gastrointestinal disorders. -
CCK-B Antagonist
GV-150013 is a selective antagonist of the cholecystokinin B (CCK-B) receptor, known for its ability to modulate neurotransmitter activity. This compound is primarily utilized in studies investigating sleep regulation and related disorders. Its distinct mechanism of action positions GV-150013 as a valuable tool for research into the pharmacological management of sleep disturbances and anxiety-related conditions. -
CKK Antagonist
JMV 167 is a potent antagonist of the peripheral cholecystokinin receptor (CKK), exhibiting an IC50 value of 500 nM. This compound is valuable for research applications involving the modulation of digestive processes and appetite regulation. Its role in studying the effects of cholecystokinin signaling makes it an essential tool for investigating therapeutic strategies related to gastrointestinal disorders and metabolic conditions. -
CCK Agonist
U-67827E is a cholecystokinin (CCK) agonist that modulates food intake by impacting gastrointestinal motility. This compound influences the latency to food consumption, potentially through the inhibition of gastric emptying and enhancement of gastric distention signaling. U-67827E is valuable for research applications investigating appetite regulation and the mechanisms of satiety. -
CCK-B Receptor Antagonist
L-740093 is a potent cholecystokinin-B (CCK-B) receptor antagonist with significant central nervous system (CNS) penetration. This compound is utilized in research to investigate the role of CCK-B receptors in various physiological and pathological processes, including anxiety and pain modulation. Its ability to effectively cross the blood-brain barrier makes it a valuable tool for exploring CNS-related mechanisms. -
CCK/Gastrin Receptor Antagonist
Benzotript is a cholecystokinin (CCK) and gastrin receptor antagonist. It exhibits significant antiproliferative effects in human colon carcinoma cell lines, making it valuable for cancer research. This compound can be employed in studies investigating the role of CCK and gastrin signaling pathways in tumor growth and development. -
CCKB Receptor Antagonist
L 368935 is a potent antagonist of the cholecystokinin B receptor (CCKB receptor), demonstrating effective brain penetration and central activity. This compound is significant for research applications focused on neuropharmacology and gastrointestinal physiology, as well as studying the roles of CCKB receptors in various neurological disorders. -
CCK2R Antagonist
CI-988 is a potent and selective antagonist of the cholecystokinin 2 receptor (CCK2R), exhibiting an IC50 of 1.7 nM in mouse cortex assays. Demonstrating over 1600-fold selectivity for CCK2 over the CCK1 receptor, CI-988 has been shown to possess anxiolytic and anti-tumor properties. This compound is valuable for research into therapeutic applications in anxiety disorders and cancer treatment. -
CCKBR Antagonist
Itriglumide is a potent and selective antagonist of the cholecystokinin B receptor (CCKBR), exhibiting an IC50 of 2.3 nM. It effectively antagonizes gastrin response in a dose-dependent manner, with an IC50 of 5.9 nM. Itriglumide demonstrates significant antisecretory and antiulcer properties, making it a valuable reagent for research in gastrointestinal pharmacology and related studies. -
Decapeptid
Caerulein, desulfated is a desulfurated form of the decapeptide Caerulein, which shares five carboxyl-terminal amino acids with gastrin and cholecystokinin (CCK). This compound primarily targets and activates CCK receptors, playing a significant role in gastrointestinal physiology. It is widely utilized in research applications focused on understanding digestive processes, appetite regulation, and modulation of pancreatic activities. -
Anorectic Agent
FPL 14294 is an intranasally active anorectic agent and cholecystokinin octapeptide (CCK) analog known for its enhanced metabolic stability. This compound effectively induces satiety across various species, making it a valuable tool for research in appetite regulation and metabolic studies. Its unique properties facilitate investigations into mechanisms of weight control and potential therapeutic interventions for obesity. -
CCK Fragment
Cholecystokinin (1-21) is a fragment of the cholecystokinin polypeptide that primarily targets the CCK receptors. This peptide is known to stimulate lipolysis in human adipose tissue, making it an important reagent for studies focused on metabolic regulation and energy homeostasis. Its application extends to research involving appetite regulation and gastrointestinal function. -
CCK-B Receptor Antagonist
LY288513 is a selective non-peptide antagonist of the cholecystokinin B (CCK-B) receptor, exhibiting an IC50 value of 16 nM. It has been demonstrated to produce anxiolytic-like effects in murine models, making it a valuable tool for research in anxiety disorders and related neurobiological studies. Its specificity for the CCK-B receptor allows for targeted investigation into the mechanisms underlying anxiety and stress responses.
